RxDoctor Payments Data

Harry Hill

Psychiatric/Mental Health · Glens Falls, NYNPI 1700033982

Payments from drug & device makers

$3,560in general payments, 2019–2025

Across 147 payments — averaging $24.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$1K
  • Otsuka America Pharmaceutical, Inc.$659
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$347
  • Teva Pharmaceuticals USA, Inc.$302
  • Neurocrine Biosciences, Inc.$229
  • Vanda Pharmaceuticals Inc.$199
  • plus $704 from 10 others

What the payments were for

  • Food & beverage$3,39695%
  • Education$1645%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,560 in reported general payments places this provider in the 85th percentile of 2,385 psychiatric/mental health providers in New York.

See all psychiatric/mental health providers in New York

Medicare billing

Part B allowed, 2024
$15,520
Medicare patients
47
Services billed
285

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate120$312,411
Abilify MaintenaAripiprazole43$123,180
IngrezzaValbenazine Tosylate14$119,369
VraylarCariprazine Hcl56$78,149
AristadaAripiprazole Lauroxil16$52,087
RexultiBrexpiprazole29$41,670
AuvelityDextromethorphan Hbr/Bupropion15$16,168
Lurasidone Hcl35$14,144
Clozapine203$9,668
Quetiapine Fumarate ErQuetiapine Fumarate25$7,910
Paliperidone ErPaliperidone25$5,618
QuviviqDaridorexant Hcl11$5,616
Olanzapine183$4,041
Haloperidol Decanoate80$3,201
Divalproex Sodium135$2,614

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$1,120$312,411120 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti$659$164,84972 claims
Neurocrine Biosciences, Inc.Ingrezza$229$119,36914 claims
AbbVieVraylar$129$78,14956 claims
Alkermes, Inc.Aristada$109$52,08716 claims
Axsome Therapeutics, Inc.Auvelity$51$16,16815 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,385 psychiatric/mental health providers in New York.

Other psychiatric/mental health in Glens Falls

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →